Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Tupulak who wrote (55)	7/6/1999 9:10:00 AM
From: Tupulak	Read Replies (1) \| Respond to of 164

Canadian Company Press Release SYB 1999-07-06 (provided courtesy of Canadian Corporate News.) register to receive future releases by email from CCN SYNSORB Biotech Inc. Board of Directors Announces Executive Changes CALGARY, ALBERTA--The Board of Directors of SYNSORB Biotech Inc. ("SYNSORB") (TSE:SYB, NASDAQ: SYBB) announced today the resignation of Dr. Brad Thompson as an officer of the company. Dr. Thompson will continue to be Chairman of the Board, and has agreed to assume the position of President and CEO of Oncolytics Biotech Inc. ("Oncolytics"), a wholly owned subsidiary of SYNSORB established to commercialize the use of the reovirus as an anticancer therapeutic. "This completes the transition of executive responsibility in SYNSORB to Dr. David Cox who was appointed CEO of SYNSORB in February of this year." said Dr. Thompson. "I will, of course, be actively supporting David and SYNSORB in my role as a Director of the company, as well as concentrating on developing Oncolytics and this important technology." "Brad and I have worked together now for many years," said Dr. David Cox, President and CEO of SYNSORB, "I am delighted that we will continue to work together on the completion of our two lead products and that Brad will play an important role in the development of our pipeline, specifically Oncolytics." SYNSORB is dedicated to accelerated drug development from the acquisition of promising compounds emerging from basic research through clinical development, and ultimately to providing channels to market for new discoveries. Headquartered in Calgary, SYNSORB currently has two products in late stage clinical development, SYNSORB Pk(R) for the prevention of HUS and the treatment of verotoxigenic E. coli (VTEC) infections (including O157:H7), and SYNSORB Cd(R) designed to treat recurrent antibiotic-associated diarrhea (CDAD). SYNSORB has additional compounds in pre-clinical development, including REOSYN, a potential cancer treatment being developed within its subsidiary company, Oncolytics, and novel antibiotics, with inflammation and anti-virals targeted in the Company's research and development program. Shares of SYNSORB Biotech Inc. trade on the Toronto Stock Exchange in Canada (symbol "SYB") and on NASDAQ in the United States (ticker "SYBB"). This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's registration statement on Form 20 F filed with the Securities and Exchange Commission. -30- FOR FURTHER INFORMATION PLEASE CONTACT: SYNSORB Biotech Inc. David Cox, Ph.D. President & CEO (403) 283-5900 (403) 283-5907 (FAX) or The Equicom Group Jason Hogan Investor Relations (416) 815-0700 ex 222 (416) 815-0080 (FAX) or Oncolytics Biotech Inc. Brad Thompson, Ph.D President & CEO (403) 283-5900 (403) 283-5907 (FAX) or SYNSORB Biotech Inc. W. Douglas Froom Vice President, Business Development (403) 283-5900 (403) 283-5907 (FAX) synsorb.com For Product Licensing Inquiries